Document is current

Article History

Received: 11 April 2024

Accepted: 10 June 2024

First Online: 22 July 2024

Declarations

:

: John Guittar, Akash Mitra, Terri Driessen, Regina Schwind, Michelle M. Stein, Kristiyana Kaneva, Seung Won Hyun, Yan Liu, Adam J. Dugan, Cecile Rose T. Vibat, Chithra Sangli, Jonathan Freaney, Zachary Rivers, Christine Lo, Kate Sasser, Rotem Ben-Shachar, and Halla Nimeiri are employees of and receive stock options from Tempus AI, Inc. Akash Mitra is an inventor on a provisional patent 63/380,510 submitted by Guardant Health to assess the efficacy of blood tumor mutation burden in predicting response to immune checkpoint blockade in non-small cell lung cancer patients and reports stock ownership with Guardant Health. Wade T. Iams discloses: a consulting or advisory role at Bristol-Myers Squibb/Pfizer, Amgen, Sanofi, Novocure, Merus, Guardant Health, Tempus AI, EMD Serono, Genentech, AstraZeneca, and Catalyst Pharmaceuticals. Jyoti D. Patel discloses: a consulting or advisory role with Abbvie, AstraZeneca, Takeda Science Foundation, Genentech, and Anheart Therapeutics; travel/accommodation expenses: Tempus AI. Aadel A. Chaudhuri discloses: stock and/or ownership interests with Geneoscopy, Droplet Biosciences and LiquidCellDX; a consulting or advisory role with Geneoscopy, Roche, Illumina, Myriad Genetics, Invitae, AstraZeneca, NuProbe, AlphaSights, GuideBio, Tempus AI, DeciBio, and Daiihi Sankyo; research funding from Roche, Illumina, and Tempus AI; patents, royalties and/or intellectual property with Droplet Biosciences, Tempus AI, LiquidCell Dx, and Biocognitive Labs; honoraria from Agielent, Roche and DAVA Oncology. Ryan D. Gentzler discloses: a consulting or advisory role at AstraZeneca, Takeda, Gilead Sciences, Janssen, Regeneron, and Merus; research funding from Bristol Myers Squibb, Merck, Takeda, Jounce therapeutics, Pfizer, Mirati Therapeutics, Janssen, RTI International, AstraZeneca, Amgen, Chugai Pharma, Dizal Pharma; honoraria from OncLive, Clinical Care Options, Aptitude Health; travel/accommodation expenses: Tempus AI. Josephine L. Feliciano discloses: consulting or advisory role at AstraZeneca, Merck, Genentech, Pfizer, Lilly, Bristol Myers Squibb, Regeneron, Coherus Biosciences, and Janssen; travel/accommodation expenses: Regeneron; research funding: Merck, Genentech, AstraZeneca, Bristol Myers Squibb, and Pfizer.

: Tempus AI, Inc. has been granted an IRB exemption (Advarra Pro00072742) permitting the use of de-identified clinical, molecular, and multimodal data in order to derive or capture results, insights, or discoveries. All patient-level data were deidentified in accordance with the Health Insurance Portability and Accountability Act (HIPAA). This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.